$SNPX
Synaptogenix, Inc.

2023 Q4 Form 10-Q Financial Statement

#000141057823002492 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.555M $1.220M $1.683M
YoY Change -65.27% -27.49% -19.6%
% of Gross Profit
Research & Development $577.9K $212.1K $1.485M
YoY Change -59.1% -85.71% 77.44%
% of Gross Profit
Depreciation & Amortization -$3.650K $10.00K $1.490K
YoY Change -340.13% 571.14% 20.16%
% of Gross Profit
Operating Expenses $2.132M $1.430M $3.167M
YoY Change -63.79% -54.86% 8.12%
Operating Profit
YoY Change
Interest Expense $821.4K $1.520M $140.7K
YoY Change -92.08% 980.08% 5644.08%
% of Operating Profit
Other Income/Expense, Net $315.0K $2.193M $140.7K
YoY Change -96.25% 1458.3%
Pretax Income -$996.0K $763.2K -$3.026M
YoY Change -122.22% -125.22% 3.4%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$1.229M $763.2K -$3.026M
YoY Change -128.16% -125.22% 3.4%
Net Earnings / Revenue
Basic Earnings Per Share $0.03 $0.43
Diluted Earnings Per Share -$1.45 $0.03 $0.43
COMMON SHARES
Basic Shares Outstanding 20.39M 10.16M 6.841M
Diluted Shares Outstanding 10.70M 6.988M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.66M $31.73M $26.33M
YoY Change -23.53% 20.49% -15.85%
Cash & Equivalents $28.66M $31.70M $26.30M
Short-Term Investments $1.439M
Other Short-Term Assets $1.871M $610.0K $995.0K
YoY Change 69.01% -38.69% -4.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $30.53M $32.34M $27.33M
YoY Change -20.87% 18.34% -15.49%
LONG-TERM ASSETS
Property, Plant & Equipment $18.51K $19.72K $21.53K
YoY Change -16.41% -8.44% 16.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $562.4K
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $580.9K $19.72K $21.53K
YoY Change 2523.21% -8.44% 16.48%
TOTAL ASSETS
Total Short-Term Assets $30.53M $32.34M $27.33M
Total Long-Term Assets $580.9K $19.72K $21.53K
Total Assets $31.11M $32.36M $27.35M
YoY Change -19.41% 18.32% -15.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $444.6K $214.2K $483.4K
YoY Change -32.65% -55.68% -48.32%
Accrued Expenses $3.832M $76.54K $200.2K
YoY Change 613.94% -61.77% 178.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.276M $1.818M $683.6K
YoY Change 225.75% 165.91% -32.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.253M $2.110M
YoY Change -33.36%
Total Long-Term Liabilities $1.253M $2.110M $0.00
YoY Change -33.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.276M $1.818M $683.6K
Total Long-Term Liabilities $1.253M $2.110M $0.00
Total Liabilities $5.529M $3.932M $683.6K
YoY Change 73.17% 475.16% -32.14%
SHAREHOLDERS EQUITY
Retained Earnings -$33.61M -$32.38M -$24.20M
YoY Change 69.48% 33.82% 144.29%
Common Stock $2.411K $1.753K $685.00
YoY Change 231.18% 155.91% 11.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.58M $26.74M $26.67M
YoY Change
Total Liabilities & Shareholders Equity $31.11M $32.36M $27.35M
YoY Change -19.41% 18.32% -15.48%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$1.229M $763.2K -$3.026M
YoY Change -128.16% -125.22% 3.4%
Depreciation, Depletion And Amortization -$3.650K $10.00K $1.490K
YoY Change -340.13% 571.14% 20.16%
Cash From Operating Activities -$1.063M -$1.170M -$2.418M
YoY Change -61.8% -51.62% 123.86%
INVESTING ACTIVITIES
Capital Expenditures $2.710K $0.00 -$2.250K
YoY Change 27.23% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$2.000M
YoY Change
Cash From Investing Activities -$2.003M $0.00 -$2.250K
YoY Change 93923.94% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.070K 0.000 0.000
YoY Change -100.01% -100.0%
NET CHANGE
Cash From Operating Activities -1.063M -1.170M -2.418M
Cash From Investing Activities -2.003M 0.000 -2.250K
Cash From Financing Activities -1.070K 0.000 0.000
Net Change In Cash -3.067M -1.170M -2.420M
YoY Change -127.52% -51.66% 494.07%
FREE CASH FLOW
Cash From Operating Activities -$1.063M -$1.170M -$2.418M
Capital Expenditures $2.710K $0.00 -$2.250K
Free Cash Flow -$1.066M -$1.170M -$2.416M
YoY Change -61.74% -51.57% 123.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001571934
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Registrant Name
EntityRegistrantName
Synaptogenix, Inc.
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40458
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1585656
dei Entity Address Address Line1
EntityAddressAddressLine1
1185 Avenue of the Americas
dei Entity Address Address Line2
EntityAddressAddressLine2
3rd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
973
dei Local Phone Number
LocalPhoneNumber
242-0005
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
SNPX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20390833
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31727549
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37478480
CY2023Q3 snpx Prepaid Clinical Trial Expenses
PrepaidClinicalTrialExpenses
375085
CY2022Q4 snpx Prepaid Clinical Trial Expenses
PrepaidClinicalTrialExpenses
367714
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
238109
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
739467
CY2023Q3 us-gaap Assets Current
AssetsCurrent
32340743
CY2022Q4 us-gaap Assets Current
AssetsCurrent
38585661
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19715
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22145
CY2023Q3 us-gaap Assets
Assets
32360458
CY2022Q4 us-gaap Assets
Assets
38607806
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
214218
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
660206
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
76543
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
536714
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
115890
CY2023Q3 snpx Temporaray Equity Accrued Amount Payable Current
TemporarayEquityAccruedAmountPayableCurrent
1527002
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1817763
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1312810
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
455000
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1510000
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1659000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
370300
CY2023Q3 us-gaap Liabilities
Liabilities
3931763
CY2022Q4 us-gaap Liabilities
Liabilities
3193110
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
snpx Temporary Equity Face Value Per Share
TemporaryEquityFaceValuePerShare
1000
CY2022 snpx Temporary Equity Face Value Per Share
TemporaryEquityFaceValuePerShare
1000
CY2023Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
9000
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
9000
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
15000
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
15000
CY2023Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
9000000
CY2023Q3 snpx Temporary Equity Liquidation Preference Percentage Of Accrued Dividends
TemporaryEquityLiquidationPreferencePercentageOfAccruedDividends
0.07
CY2023Q3 snpx Temporary Equity Liquidation Preference Amount Of Accrued Dividends
TemporaryEquityLiquidationPreferenceAmountOfAccruedDividends
128625
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
1687835
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
2721723
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17510743
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17510743
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7267032
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7267032
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1753
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
728
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
59120436
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52523762
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32381329
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19831517
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
26740860
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32692973
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32360458
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38607806
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
212103
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1484694
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1397031
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4911869
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1217689
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1682512
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4784415
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5334260
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1429792
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
3167206
us-gaap Operating Expenses
OperatingExpenses
6181446
us-gaap Operating Expenses
OperatingExpenses
10246129
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
549995
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
140730
us-gaap Interest Income Other
InterestIncomeOther
1373511
us-gaap Interest Income Other
InterestIncomeOther
189827
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-674000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1055000
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
969000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1289600
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2192995
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
140730
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1138911
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
189827
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
763203
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3026476
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5042535
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10056302
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
763203
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3026476
us-gaap Net Income Loss
NetIncomeLoss
-5042535
us-gaap Net Income Loss
NetIncomeLoss
-10056302
CY2023Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1124628
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1814277
snpx Deemed Dividend Related To Temporary Equity Extinguishment
DeemedDividendRelatedToTemporaryEquityExtinguishment
5693000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-361425
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3026476
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12549812
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10056302
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.43
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.44
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10702900
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10702900
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6988000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6988000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8476200
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8476200
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6962400
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6962400
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
28953273
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
510747
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
75000
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
154503
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3026476
CY2022Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
26667047
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
24830127
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15064
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
4500
CY2023Q3 snpx Adjustments To Temporary Equity Dividends
AdjustmentsToTemporaryEquityDividends
192500
CY2023Q3 snpx Deemed Dividend Temporary Equity Extinguishment
DeemedDividendTemporaryEquityExtinguishment
-116757
CY2023Q3 snpx Temporary Equity Redemption Value
TemporaryEquityRedemptionValue
-3892879
CY2023Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2455656
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
763203
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
26740860
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33529748
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2238995
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
146603
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
254853
snpx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
553150
us-gaap Net Income Loss
NetIncomeLoss
-10056302
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
26667047
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32692973
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
994261
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
113500
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
882149
snpx Adjustment To Additional Paid In Capital Temporary Equity Extinguishment Of Deemed Dividend
AdjustmentToAdditionalPaidInCapitalTemporaryEquityExtinguishmentOfDeemedDividend
-116757
snpx Temporary Equity Redemption Value
TemporaryEquityRedemptionValue
-3892879
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4911312
us-gaap Net Income Loss
NetIncomeLoss
-5042535
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
26740860
us-gaap Net Income Loss
NetIncomeLoss
-5042535
us-gaap Net Income Loss
NetIncomeLoss
-10056302
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
994261
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2238995
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1055000
snpx Fair Value Of Derivative Liability
FairValueOfDerivativeLiability
-1289600
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
113500
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
254853
snpx Issuance Of Stock And Warrants For Services
IssuanceOfStockAndWarrantsForServices
146603
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5137
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4188
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-493987
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-295253
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-445988
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-813116
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-460171
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-498201
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
935326
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1628575
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4107209
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8427727
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2707
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5275
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2707
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5275
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
553150
snpx Payments To Redemption Of Temporary Equity
PaymentsToRedemptionOfTemporaryEquity
1000000
snpx Payments To Dividends Of Temporary Equity
PaymentsToDividendsOfTemporaryEquity
641015
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1641015
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
553150
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5750931
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7879852
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37478480
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34213989
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31727549
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26334137
us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
1173262
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4911312
snpx Temporary Equity Modification Deemed Dividend
TemporaryEquityModificationDeemedDividend
5693000
snpx Temporary Equity Accrual Dividend Redemption
TemporaryEquityAccrualDividendRedemption
1527002
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1 – Organization, Business, Risks and Uncertainties:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Organization and Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 17, 2020, Neurotrope, Inc. (“Neurotrope” or “the Parent”) announced plans for the complete legal and structural separation of its wholly owned subsidiary, Neurotrope Bioscience, Inc., from Neurotrope (the “Spin-Off”). Under the Separation and Distribution Agreement, Neurotrope planned to distribute all of its equity interest in this wholly owned subsidiary to Neurotrope’s stockholders. Following the Spin-Off, Neurotrope does not own any equity interest in the Company, and the Company operates independently from Neurotrope. On December 7, 2020, the Company became an independent company, Synaptogenix, Inc., a Delaware corporation (formerly known as Neurotrope Bioscience, Inc.) (the “Company” or “Synaptogenix”) when the Company filed an amended and restated certificate of incorporation which, among other things, changed its name to Synaptogenix, Inc. The Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), are listed on The Nasdaq Capital Market under the symbol “SNPX.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Neurotrope Bioscience, Inc. was incorporated in Delaware on October 31, 2012 to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). The Company is collaborating with Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February 28, 2013 (see Note 4 - Related Party Transactions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the separation from Neurotrope, the Company entered into a Separation and Distribution Agreement and several other ancillary agreements. These agreements govern the relationship between the parties after the separation and allocate between the parties’ various assets, liabilities, rights and obligations following the separation, including employee benefits, intellectual property, information technology, insurance and tax-related liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2022, the Company issued a press release announcing that an extended confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD (Study #204) did not achieve statistical significance on the primary endpoint, which was changed from baseline to Week 13 in the Severe Impairment Battery (“SIB”) total score assessment obtained after completion of the second seven-dose course of treatment (week 28 of trial). On March 7, 2023, the Company announced results of its analysis of secondary endpoints and post hoc analysis from our Phase 2 study of Bryostatin-1. In the secondary endpoint analysis, changes from baseline at Weeks 9, 20, 24, 30, and 42 in the SIB (Severe Impairment Battery) total score were not statistically significant in the total patient population, and no pre-specified secondary endpoints were met with statistical significance in the low-to-moderately severe AD patient stratum. However, nearly all pre-specified secondary endpoints in the most advanced and severe AD (Mini Mental State Exam 2 (“MMSE”) (baseline scores: 10-14) patient population, with baseline MMSE-2 (Mini-Mental State Examination, 2nd Edition) scores of 10-14, were achieved with statistical significance (p = &lt;0.05, 2-tailed). Data also showed statistical significance in exploratory secondary endpoints for the MMSE-2 10-14 stratum, and post hoc analysis was positive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 24, 2023, the Company received a written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days, the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company received an initial grace period of 180 calendar days, or until October 23, 2023 (the “Initial Compliance Period”), to regain compliance with the Minimum Bid Price Requirement. Compliance could be achieved automatically and without further action if the closing bid price of the Company’s stock remained at or above $1.00 for a minimum of 10 consecutive business days at any time during the Initial Compliance Period. On October 24, 2023, the Company received a second written notice from Nasdaq, notifying the Company that it had not regained compliance with the Minimum Bid Price Requirement during the Initial Compliance Period and granting the Company an additional grace period of 180 calendar days, or until April 22, 2024 (the “Second Compliance Period”), to regain compliance. Compliance can be achieved automatically and without further action if the closing bid price of the Company’s stock remains at or above $1.00 for a minimum of 10 consecutive business days at any time during the Second Compliance Period, in which case Nasdaq will notify the Company of its compliance and the matter will be closed.  If, however, the Company does not achieve compliance with the Minimum Bid Price Requirement during the Second Compliance Period, Nasdaq will notify the Company that its common stock will be delisted subject to an opportunity for the Company to appeal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2023, the Company had approximately $31.7 million in cash and cash equivalents as compared to $37.5 million at December 31, 2022. The Company expects that its current cash and cash equivalents, approximately $29.5 million as of the date of this Quarterly Report on Form 10-Q, will be sufficient to support its projected operating requirements and financial commitments for at least the next 12 months from this date. The operating requirements include the current development plans for Bryostatin-1, our novel drug candidate targeting the activation of Protein Kinase C Epsilon and other development projects. The financial commitments include the potential redemption of the Series B Convertible Preferred Stock for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expects to need additional capital in order to initiate and pursue potential additional development projects, including the continuing development beyond the ongoing Phase 2 trial of Bryostatin-1. Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders, and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its technologies or product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates in an industry that is subject to rapid technological change, intense competition, and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological and regulatory. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the limited supply of raw materials, the ability to obtain favorable licensing, manufacturing or other agreements, including risk associated with our CRE licensing agreement, and the ability to raise capital to achieve strategic objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CRE has entered into a material transfer agreement with the National Cancer Institute of the National Institutes of Health (“NCI”), pursuant to which the NCI has agreed to supply bryostatin required for the Company’s pre-clinical research and clinical trials. This agreement does not provide for a sufficient amount of bryostatin to support the completion of all of the clinical trials that the Company is required to conduct in order to seek U.S. Food and Drug Administration (“FDA”) approval. Therefore, CRE or the Company would have to enter into one or more subsequent agreements with the NCI for the supply of additional amounts of bryostatin. If CRE or the Company were unable to secure such additional agreements, or if the NCI otherwise discontinues the supply, the Company would have to either secure another source of bryostatin or discontinue its efforts to develop and commercialize Bryostatin-1 for the treatment of AD. In June 2020, the Company entered into a supply agreement (the “Supply Agreement”) with BryoLogyx Inc. (“BryoLogyx”), pursuant to which BryoLogyx agreed to be the Company’s exclusive supplier of synthetic bryostatin. Pursuant to the terms of the Supply Agreement, the Company received its initial order of one gram of synthetic bryostatin. See Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company also faces the ongoing risk that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company’s future trials. In order to prioritize patient health and that of the investigators at clinical trial sites, we will monitor enrollment of new patients in our future clinical trials. In addition, some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. These and other factors outside of our control could delay our ability to conduct clinical trials or release clinical trial results. In addition, the effects of a pandemic resurgence may also increase non-trial costs such as insurance premiums, increase the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key clinical trial vendors and suppliers.</p>
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 snpx Number Of Preceding Consecutive Business Days Failure To Maintain Minimum Closing Bid Price
NumberOfPrecedingConsecutiveBusinessDaysFailureToMaintainMinimumClosingBidPrice
30
CY2023Q2 snpx Minimum Closing Bid Price Failed To Maintain In Preceding Thirty Consecutive Business Days
MinimumClosingBidPriceFailedToMaintainInPrecedingThirtyConsecutiveBusinessDays
1.00
CY2023Q2 snpx Number Of Calendar Days Of Grace Period To Attain Minimum Closing Bid Price
NumberOfCalendarDaysOfGracePeriodToAttainMinimumClosingBidPrice
180
CY2023Q2 snpx Stock Priceto Be Maintained For Minimum Of Ten Consecutive Business Days In Grace Period To Achieve Compliance
StockPricetoBeMaintainedForMinimumOfTenConsecutiveBusinessDaysInGracePeriodToAchieveCompliance
1.00
CY2023Q2 snpx Number Of Minimum Consecutive Business Days In Grace Period To Attain Minimum Bid Price Requirement To Achieve Compliance
NumberOfMinimumConsecutiveBusinessDaysInGracePeriodToAttainMinimumBidPriceRequirementToAchieveCompliance
10
CY2023Q2 snpx Number Of Calendar Days Of Grace Period To Attain Minimum Closing Bid Price
NumberOfCalendarDaysOfGracePeriodToAttainMinimumClosingBidPrice
180
CY2023Q2 snpx Stock Priceto Be Maintained For Minimum Of Ten Consecutive Business Days In Grace Period To Achieve Compliance
StockPricetoBeMaintainedForMinimumOfTenConsecutiveBusinessDaysInGracePeriodToAchieveCompliance
1.00
CY2023Q2 snpx Number Of Minimum Consecutive Business Days In Grace Period To Attain Minimum Bid Price Requirement To Achieve Compliance
NumberOfMinimumConsecutiveBusinessDaysInGracePeriodToAttainMinimumBidPriceRequirementToAchieveCompliance
10
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31700000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37500000
CY2023Q3 snpx Cash And Cash Equivalents Expected Amount At Financial Reporting Date
CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate
29500000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
snpx Number Of Votes Per Share Owned
NumberOfVotesPerShareOwned
1
CY2023Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1527001
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
969000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1289600
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management’s best judgment at a point in time and as such these estimates may ultimately differ from actual results.</p>
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9280092
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5800897
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9254504
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6249383
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
1500000
CY2023Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
30200000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
625000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
625000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
661850
CY2023Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P2Y
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Receivable
OperatingLeasesFutureMinimumPaymentsReceivable
50000
CY2023Q3 snpx Capitalized Research And Development Services
CapitalizedResearchAndDevelopmentServices
0
CY2022Q4 snpx Capitalized Research And Development Services
CapitalizedResearchAndDevelopmentServices
0
CY2023Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
94000000.0
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27600000
snpx Grant Related Expense Reductions Recognized
GrantRelatedExpenseReductionsRecognized
0
snpx Grant Related Expense Reductions Recognized
GrantRelatedExpenseReductionsRecognized
100000
CY2022Q3 snpx Grant Related Expense Reductions Recognized
GrantRelatedExpenseReductionsRecognized
100000
snpx Number Of Statements Of Work Agreements Entered
NumberOfStatementsOfWorkAgreementsEntered
0
CY2021 snpx Number Of Statements Of Work Agreements Entered
NumberOfStatementsOfWorkAgreementsEntered
0
CY2022 snpx Number Of Statements Of Work Agreements Entered
NumberOfStatementsOfWorkAgreementsEntered
0
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.27
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
80000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.87
snpx Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P10Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
741850
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
661850
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y9M18D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023Q3 us-gaap Share Price
SharePrice
0.44
CY2022Q4 us-gaap Share Price
SharePrice
1.16
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
30000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y6M
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15064
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
994271
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10612
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
58530
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
6265525
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
2028762
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
65000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
1049368
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
7179919
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.79
CY2023Q3 snpx Warrants And Rights Outstanding Remaining Term
WarrantsAndRightsOutstandingRemainingTerm
P2Y10M28D
CY2023Q3 snpx Intrinsic Value Of Warrants
IntrinsicValueOfWarrants
62000
CY2023Q3 snpx Class Of Warrant Or Rights Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights
0.44
CY2022Q3 snpx Number Of Warrant Holders Who Exercised Warrants
NumberOfWarrantHoldersWhoExercisedWarrants
0
snpx Number Of Warrant Holders Who Exercised Warrants
NumberOfWarrantHoldersWhoExercisedWarrants
0
CY2023Q3 snpx Number Of Warrant Holders Who Exercised Warrants
NumberOfWarrantHoldersWhoExercisedWarrants
0

Files In Submission

Name View Source Status
snpx-20230930_pre.xml Edgar Link unprocessable
0001410578-23-002492-index-headers.html Edgar Link pending
0001410578-23-002492-index.html Edgar Link pending
0001410578-23-002492.txt Edgar Link pending
0001410578-23-002492-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snpx-20230930.xsd Edgar Link pending
snpx-20230930x10q.htm Edgar Link pending
snpx-20230930xex31d1.htm Edgar Link pending
snpx-20230930xex31d2.htm Edgar Link pending
snpx-20230930xex32d1.htm Edgar Link pending
snpx-20230930xex32d2.htm Edgar Link pending
snpx-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
snpx-20230930_lab.xml Edgar Link unprocessable
snpx-20230930_def.xml Edgar Link unprocessable
snpx-20230930x10q_htm.xml Edgar Link completed